Drug Approval | March 22, 2022
Merck’s Keytruda approved for fourth gynecologic cancer indication
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
This collaboration has resulted in several high-impact scientific publications describing breakthrough inventions, including the SOMA robotic pill, which has subsequently been licensed exclusively to Novo Nordisk for clinical development
The facility is spread across 215000 sq. feet and provides super-speciality care
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years
On track to complete the BLA submission in the first half of 2022
The collaboration will leverage EdiGene’s expertise in high-throughput genome editing screening and Neukio’s strength in the development and manufacturing of induced pluripotent stem cell (iPSC) and natural killer cell (NK Cell)
The appointment is key for DefiniGEN as they expand the service portfolio to encompass compound screening
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
Subscribe To Our Newsletter & Stay Updated
